orelabrutinib + gemcitabine + oxaliplatin

A combination therapy consisting of orelabrutinib (a BTK inhibitor) with gemcitabine and oxaliplatin. The gemcitabine and oxaliplatin (GEMOX/GemOx) component is a well-established chemotherapy regimen used in various cancers including pancreatic cancer, biliary tract cancer, hepatocellular carcinoma, and relapsed/refractory lymphomas. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while oxaliplatin is a platinum-based agent that forms DNA adducts leading to cell death. The addition of orelabrutinib, a Bruton's tyrosine kinase inhibitor, to this regimen is not well documented in the current literature.

Other names

orelabrutinib + GEMOX